4sc Ag

4sc Discovery Gmbh

Rolf Krauss

Stefan Tasler

Frank Totzke

Michael Kubbutat

Martin Lang

Christoph Schaechtele

Thomas Herz

Michael Gassen

Wael Saeb

Bernd Kramer

Stefano Pegoraro

Kristina Wolf

Juergen Kraus

Johan Leban

Gabriel Garcia

Elke Martin

Bernd Hentsch

Alexander B Maurer

Andrea Aschenbrenner

Katharina Aulinger Fuchs

Matthias Dormeyer

Adam-Spencer Vincek

Jürgen Kraus

Sascha Hoevelmann

The present invention relates to compounds as inhibitors of enzymes having histone deacetylase activity, to the processes for the preparation of those compounds, and to their use for the treatment of diseases which are associated with hypoacetylation of histones and/or other molecules, or in which induction of hyperacetylation has a beneficial effect for example by inhibition of proliferation and/or induction of differentiation and/or induction of apoptosis in transformed cells, such as cancer. Furthermore, the compounds are useful for the treatment of other proliferative diseases, for therapy or prophylaxis of conditions associated with abnormal gene expression.

Compounds as histone deacetylase inhibitors

The present invention relates to compounds of the general formulas (I), (Ia) and (II) and salts and physiologically functional derivatives thereof, whereinthe substituents &#x2014;Y are attached to the 5- or 6-position of the benzazole.

Benzazole analogues and uses thereof

The present invention relates to N-heteroaryl-benzazole-2,(5 or 6)-diamine derivatives and compositions thereof as protein kinase inhibitors for the treatment of e.g. cancer.

The invention relates to new diphenylurea having the formula (I)or a salt thereof, where

Compounds for the treatment of protozoal diseases

Growing community of inventors

Planegg-Martinsried, Germany

Rolf Krauss